ArticleNeuro-oncology advances
A novel fully automated MRI-based deep-learning method for classification of 1p/19q co-deletion status in brain gliomas.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Diagnostic performance of deep learning for predicting glioma isocitrate dehydrogenase and 1p/19q co-deletion in MRI: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Deep learning-based segmentation, grading and genotype classification of glioma: a literature analysis.Quantitative imaging in medicine and surgery · 2026Review
- Review
- AI-Driven Innovations in Neuroradiology and Neurosurgery: Scoping Review of Current Evidence and Future Directions.Cancers · 2025Review
- Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements.The Lancet. Oncology · 2024Review
- Assessment of artificial intelligence (AI) reporting methodology in glioma MRI studies using the Checklist for AI in Medical Imaging (CLAIM).Neuroradiology · 2023Article
- Uncertainty-Aware Deep Learning Classification of Adamantinomatous Craniopharyngioma from Preoperative MRI.Diagnostics (Basel, Switzerland) · 2023Article
- Artificial intelligence in neuro-oncology.Frontiers in neuroscience · 2023Review
- Artificial intelligence for multimodal data integration in oncology.Cancer cell · 2022Review
- Swin Transformer Improves the IDH Mutation Status Prediction of Gliomas Free of MRI-Based Tumor Segmentation.Journal of clinical medicine · 2022Article
- Prediction of glioma-subtypes: comparison of performance on a DL classifier using bounding box areas versus annotated tumors.BMC biomedical engineering · 2022Article
- Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.Neuro-oncology · 2022Article
- Deep learning approaches to non-invasively assess molecular features of gliomas.Neuro-oncology · 2022Article
- Predicting 1p/19q co-deletion status from magnetic resonance imaging using deep learning in adult-type diffuse lower-grade gliomas: a discovery and validation study.Laboratory investigation; a journal of technical methods and pathology · 2022Article
- Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma.Frontiers in oncology · 2022Article
- Introduction to Deep Learning in Clinical Neuroscience.Acta neurochirurgica. Supplement · 2022Article
- Brain tumor IDH, 1p/19q, and MGMT molecular classification using MRI-based deep learning: an initial study on the effect of motion and motion correction.Journal of medical imaging (Bellingham, Wash.) · 2022Article
- Multimodal MRI Image Decision Fusion-Based Network for Glioma Classification.Frontiers in oncology · 2022Article
- Combining Radiology and Pathology for Automatic Glioma Classification.Frontiers in bioengineering and biotechnology · 2022Article
- Molecular Biology in Treatment Decision Processes-Neuro-Oncology Edition.International journal of molecular sciences · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundOne of the most important recent discoveries in brain glioma biology has been the identification of the isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status as markers for therapy and prognosis. 1p/19q co-deletion is the defining genomic marker for oligodendrogliomas and confers a better prognosis and treatment response than gliomas without it. Our group has previously developed a highly accurate deep-learning network for determining IDH mutation status using T2-weighted (T2w) MRI only. The purpose of this study was to develop a similar 1p/19q deep-learning classification network.
methodsMultiparametric brain MRI and corresponding genomic information were obtained for 368 subjects from The Cancer Imaging Archive and The Cancer Genome Atlas. 1p/19 co-deletions were present in 130 subjects. Two-hundred and thirty-eight subjects were non-co-deleted. A T2w image-only network (1p/19q-net) was developed to perform 1p/19q co-deletion status classification and simultaneous single-label tumor segmentation using 3D-Dense-UNets. Three-fold cross-validation was performed to generalize the network performance. Receiver operating characteristic analysis was also performed. Dice scores were computed to determine tumor segmentation accuracy.
results1p/19q-net demonstrated a mean cross-validation accuracy of 93.46% across the 3 folds (93.4%, 94.35%, and 92.62%, SD = 0.8) in predicting 1p/19q co-deletion status with a sensitivity and specificity of 0.90 ± 0.003 and 0.95 ± 0.01, respectively and a mean area under the curve of 0.95 ± 0.01. The whole tumor segmentation mean Dice score was 0.80 ± 0.007.
conclusionWe demonstrate high 1p/19q co-deletion classification accuracy using only T2w MR images. This represents an important milestone toward using MRI to predict glioma histology, prognosis, and response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.